AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
TG Therapeutics, Inc.
Video analysis: TGTX
All videosNo video analysis for this stock yet. Request one from our team.
News: TGTX
TG Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
Fireside chat scheduled for Monday, September 14, 2026, at 12:00pm ET Fireside chat scheduled for Monday, September 14, 2026, at 12:00pm ET
TG Therapeutics to Participate in the Cantor Global Healthcare Conference
NEW YORK, Sept. 03, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S.
TG Therapeutics (TGTX) Up 15.1% Since Last Earnings Report: Can It Continue?
TG Therapeutics (TGTX) reported earnings 30 days ago. What's next for the stock?
TG Therapeutics: Briumvi's Peak May Be Far Away (Rating Upgrade)
TG Therapeutics, Inc.'s Q4 2026/H1 2027 will be rich in catalysts. From the presentation of preliminary Phase 1 azer-cel data in progressive MS in the second half of 2026 to topline Phase 3 data for Briumvi SC by year-end 2026/early 2027. TG Therapeutics raised its Briumvi U.S. net product revenue from $885-$900 million to $890-$905 million.
235,481 Shares in TG Therapeutics, Inc. $TGTX Bought by Deutsche Bank AG
Deutsche Bank AG purchased a new stake in TG Therapeutics, Inc. (NASDAQ: TGTX) in the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 235,481 shares of the biopharmaceutical company's stock, valued at approximately $12,937,000. Deutsche Bank AG owned 0.15%
TG Therapeutics: Briumvi's Growth Attracts Buyout Rumors
Shares of TG Therapeutics rose this week after buyout rumors surfaced. TG is a prime takeover target, fueled by Briumvi's growth and recent subcutaneous formulation de-risking. I see a potential acquisition premium of at least 45-50%, valuing TGTX at $73-76 per share, with strong standalone prospects regardless of M&A outcomes.
Bank of America Corp DE Purchases 610,195 Shares of TG Therapeutics, Inc. $TGTX
Bank of America Corp DE lifted its position in TG Therapeutics, Inc. (NASDAQ: TGTX) by 71.7% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,461,302 shares of the biopharmaceutical company's stock after buying an additional 610,195 shares
Assenagon Asset Management S.A. Lowers Stock Position in TG Therapeutics, Inc. $TGTX
Assenagon Asset Management S.A. decreased its holdings in shares of TG Therapeutics, Inc. (NASDAQ: TGTX) by 82.0% during the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 91,681 shares of the biopharmaceutical company's stock after selling 418,373 shares during the period. Assenagon Asset
